Hudson Bay Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Hudson Bay Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.57M	Sell	350,000 -325,000	-48%	-$1.42M	0.01%	805
2025 Q4	$3.25M	Sell	675,000 -125,000	-16%	-$562K	0.01%	609
2025 Q3	$3.63M	Sell	800,000 -165,000	-17%	-$606K	0.01%	634
2025 Q2	$2.98M	Sell	965,000 -280,900	-23%	-$933K	0.01%	690
2025 Q1	$4.35M	Buy	1,245,900 +133,400	+12%	+$445K	0.01%	632
2024 Q4	$3.64M	Buy	1,112,500 +82,500	+8%	+$303K	0.01%	560
2024 Q3	$3.97M	Sell	1,030,000 -655,000	-39%	-$2.51M	0.02%	461
2024 Q2	$5.21M	Sell	1,685,000 -1,835,382	-52%	-$5.51M	0.02%	364
2024 Q1	$9.08M	Sell	3,520,382 -619,522	-15%	-$1.6M	0.05%	184
2023 Q4	$10.3M	Sell	4,139,904 -10,000	-0.2%	-$19.6K	0.07%	176
2023 Q3	$8.42M	Buy	4,149,904 +1,302,978	+46%	+$2.73M	0.07%	188
2023 Q2	$6.55M	Buy	2,846,926 +110,500	+4%	+$288K	0.05%	257
2023 Q1	$8.29M	Sell	2,736,426 -2,114,990	-44%	-$5.97M	0.07%	199
2022 Q4	$11.3M	Sell	4,851,416 -110,479	-2%	-$264K	0.12%	151
2022 Q3	$9.48M	Buy	4,961,895 +293,668	+6%	+$691K	0.08%	193
2022 Q2	$12.7M	Buy	4,668,227 +184,900	+4%	+$473K	0.1%	141
2022 Q1	$13.4M	Buy	4,483,327 +2,677,627	+148%	+$8.2M	0.18%	88
2021 Q4	$7.02M	Buy	1,805,700 +5,700	+0.3%	+$22.1K	0.07%	230
2021 Q3	$7.72M	Hold	1,800,000	–	–	0.1%	199
2021 Q2	$5.45M	Buy	1,800,000 +400,000	+29%	+$1.24M	0.07%	312
2021 Q1	$4.66M	Buy	1,400,000 +675,000	+93%	+$2.6M	0.06%	323
2020 Q4	$2.57M	Buy	725,000 +15,000	+2%	+$52.5K	0.03%	339
2020 Q3	$2.22M	Sell	710,000 -265,000	-27%	-$806K	0.03%	342
2020 Q2	$1.77M	Buy	975,000 +175,000	+22%	+$286K	0.03%	328
2020 Q1	$808K	Sell	800,000 -50,000	-6%	-$135K	0.02%	347
2019 Q4	$2.36M	Sell	850,000 -45,000	-5%	-$72.8K	0.05%	261
2019 Q3	$1.36M	Buy	895,000 +10,000	+1%	+$17.2K	0.04%	291
2019 Q2	$1.84M	Buy	885,000 +235,000	+36%	+$601K	0.04%	285
2019 Q1	$2.33M	Hold	650,000	–	–	0.03%	437
2018 Q4	$2.49M	Buy	650,000 +500,000	+333%	+$2.46M	0.03%	459
2018 Q3	$1.42M	Sell	150,000 -35,000	-19%	-$348K	0.02%	528
2018 Q2	$1.35M	Sell	185,000 -175,000	-49%	-$1.04M	0.02%	590
2018 Q1	$1.8M	Sell	360,000 -40,000	-10%	-$212K	0.04%	470
2017 Q4	$2.02M	Buy	400,000 +282,000	+239%	+$1.65M	0.04%	316
2017 Q3	$732K	Sell	118,000 -177,000	-60%	-$757K	0.02%	314
2017 Q2	$1.06M	Buy	295,000 +37,012	+14%	+$127K	0.02%	405
2017 Q1	$838K	Buy	+257,988	New	+$716K	0.01%	649

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Hudson Bay Capital Management's ABUS Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Arbutus Biopharma (ABUS) stake by 48% in Q1 2026, selling an estimated $1.42M and leaving 350,000 shares worth $1.57M. The position accounts for 0.01% of the portfolio, ranked #805.

Hudson Bay Capital Management first reported a position in ABUS in Q1 2017 and has held it in 37 quarters since. The position peaked at $13.4M in Q1 2022. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Hudson Bay Capital Management held 350,000 shares of Arbutus Biopharma worth $1.57M as of Q1 2026.
Hudson Bay Capital Management sold 325,000 Arbutus Biopharma shares in Q1 2026, an estimated $1.42M.
Arbutus Biopharma made up 0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #805 holding.
Hudson Bay Capital Management first reported a position in Arbutus Biopharma in Q1 2017 and has held it in 37 quarters since.
Hudson Bay Capital Management's Arbutus Biopharma position peaked at $13.4M in Q1 2022.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.